Outstanding Recoveries
- Home
- Outstanding Recoveries
Verdicts & Settlements
Since Milberg’s founding in 1965, the firm has recovered more than $50 billion for our clients while prompting meaningful changes in corporate governance.
Filter By
Select Practice Area
-
See More$75 Million Settlement – Irvine v. ImClone Systems, Inc.
Irvine v. ImClone Systems, Inc., No. 02-0109 (S.D.N.Y.)Milberg served as Co-Lead Counsel in this case, in which the plaintiffs alleged that ImClone misrepresented the likelihood that its drug, Erbitux, would be approved, thereby artificially inflating the price of ImClone stock. The court approved a $75 million cash settlement in 2005. -
See MoreTrump Hotels Shareholder Derivative Litigation
In re Trump Hotels Shareholder Derivative Litigation, No. 96-7820 (S.D.N.Y.)The plaintiff shareholders asserted various derivative claims on behalf of the company against certain Trump entities and senior Trump executives in connection with the sale of a casino to a company in which the plaintiffs owned stock. Milberg negotiated a settlement requiring the company to increase the number of directors and the review of certain future transactions by a special committee. -
See More$120 Million Settlement – Deutsche Telekom AG Securities Litigation
In re CVS Corp. Securities Litigation, No. 01-11464 (D. Mass.)Milberg served as Co-Lead Counsel in this securities action on behalf of a class of purchasers of American Depository Receipts. The plaintiffs alleged that Deutsche Telekom improperly failed to disclose plans to make a major corporate acquisition and overstated the value of real estate assets. In 2005, following extensive discovery, including depositions in Germany, the court approved a $120 million cash settlement. -
See More$110 Million Settlement – CVS Corp. Securities Litigation
In re CVS Corp. Securities Litigation, No. 01-11464 (D. Mass.)Milberg served as Co-Lead Counsel in this securities class action alleging that defendants issued false and misleading statements, which artificially inflated the price of CVS stock. In 2005, the court approved a $110 million settlement. -
See More$1 Billion+ Trial Verdict – Vivendi Universal, S.A. Securities Litigation
In re Vivendi Universal, S.A. Securities Litigation, No. 02-CV-5571 (S.D.N.Y.)Milberg was one of two Lead Trial Counsel in this securities fraud case tried to a jury over four months in 2009-2010. The jury found Vivendi liable for dozens of false or misleading statements and awarded damages valued at well over a billion dollars. Six months later, in an unrelated case, the Supreme Court ruled that purchasers on foreign securities exchanges could not recover under U.S. law. Our case against Vivendi continued with post-verdict proceedings under the new standard, and damages have been distributed to U.S. class members totaling over $100 million.
